Search CatalystAlert
Search for companies, drugs, and catalysts
Search CatalystAlert
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No catalyst events have been recorded for this drug yet.
0 competitors in Moderate to Severe Pain Due to Diabetic Polyneuropathy
View Full LandscapeTarget Indication
Moderate to Severe Pain Due to Diabetic Polyneuropathy
Clinical Trial
NCT00944697Last updated: 1/14/2026
No patent data available. Pre-approval drugs may not have Orange Book listings.
Nyxoid
Nyxoid is intended for immediate administration as emergency therapy for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression in both non-medical and healthcare settings. Nyxoid is indicated in adults and adolescents aged 14 years and over. Nyxoid is not a substitute for emergency medical care.
View on EMA